RhumbLine Advisers’s Bioventus BVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$549K Buy
58,188
+2,910
+5% +$27.8K ﹤0.01% 2700
2026
Q1
$505K Sell
55,278
-546
-1% -$4.58K ﹤0.01% 2607
2025
Q4
$415K Sell
55,824
-8,451
-13% -$60.7K ﹤0.01% 2786
2025
Q3
$430K Sell
64,275
-818
-1% -$5.68K ﹤0.01% 2794
2025
Q2
$431K Buy
65,093
+11,133
+21% +$78.9K ﹤0.01% 2780
2025
Q1
$494K Sell
53,960
-873
-2% -$8.72K ﹤0.01% 2584
2024
Q4
$576K Buy
54,833
+297
+0.5% +$3.51K ﹤0.01% 2585
2024
Q3
$652K Buy
54,536
+2,099
+4% +$18.1K ﹤0.01% 2529
2024
Q2
$302K Buy
52,437
+51,478
+5,368% +$282K ﹤0.01% 3001
2024
Q1
$4.99K Hold
959
– – ﹤0.01% 3985
2023
Q4
$5.05K Hold
959
– – ﹤0.01% 3983
2023
Q3
$3.16K Sell
959
-3,817
-80% -$13.4K ﹤0.01% 4051
2023
Q2
$13.8K Sell
4,776
-43,000
-90% -$82.5K ﹤0.01% 3871
2023
Q1
$51K Buy
47,776
+277
+0.6% +$530 ﹤0.01% 2905
2022
Q4
$124K Buy
47,499
+156
+0.3% +$681 ﹤0.01% 2878
2022
Q3
$331K Buy
47,343
+2,626
+6% +$20.6K ﹤0.01% 2687
2022
Q2
$305K Buy
44,717
+16,517
+59% +$169K ﹤0.01% 2743
2022
Q1
$398K Buy
28,200
+8,055
+40% +$108K ﹤0.01% 2523
2021
Q4
$292K Buy
+20,145
New +$286K ﹤0.01% 2713

Other funds holding BVS

RhumbLine Advisers's BVS Position: Q2 2026 in Review

RhumbLine Advisers increased its Bioventus (BVS) stake by 5.3% in Q2 2026, buying an estimated $27.8K and bringing the position to 58,188 shares worth $549K. The position accounts for ﹤0.01% of the portfolio, ranked #2700.

RhumbLine Advisers first reported a position in BVS in Q4 2021 and has held it in 19 quarters since. The position peaked at $652K in Q3 2024. 156 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

  • RhumbLine Advisers held 58,188 shares of Bioventus worth $549K as of Q2 2026.
  • RhumbLine Advisers bought 2,910 Bioventus shares in Q2 2026, an estimated $27.8K.
  • Bioventus made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2700 holding.
  • RhumbLine Advisers first reported a position in Bioventus in Q4 2021 and has held it in 19 quarters since.
  • RhumbLine Advisers's Bioventus position peaked at $652K in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.